Intravenous Immunoglobulin as an Immunomodulating Agent in Antineutrophil Cytoplasmic Antibody-Associated Vasculitides: A French Nationwide Study of Ninety-Two Patients.

Date publication

mars 2016

Journal

Arthritis & rheumatology (Hoboken, N.J.)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MARTIN Thierry

Tous les auteurs :
Crickx E, Machelart I, Lazaro E, Kahn JE, Cohen-Aubart F, Martin T, Mania A, Hatron PY, Hayem G, Blanchard-Delaunay C, de Moreuil C, Le Guenno G, Vandergheynst F, Maurier F, Crestani B, Dhote R, Silva NM, Ollivier Y, Mehdaoui A, Godeau B, Mariette X, Cadranel J, Cohen P, Puéchal X, Le Jeunne C, Mouthon L, Guillevin L, Terrier B,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/26473632

Résumé

Intravenous immunoglobulin (IVIG) represents a therapeutic alternative in antineutrophil cytoplasmic antibody-associated vasculitides (AAV), but its efficacy has been evaluated in only 2 small prospective trials. The aim of this study was to evaluate the efficacy and safety of IVIG in patients with AAV.

Mots clés

Adolescent, Adult, Aged, Aged, 80 and over, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, drug therapy, Antibodies, Antineutrophil Cytoplasmic, blood, Churg-Strauss Syndrome, drug therapy, Corticosterone, administration & dosage, Female, Fluorescent Antibody Technique, Humans, Immune Tolerance, Immunoglobulins, Intravenous, administration & dosage, Immunomodulation, Immunosuppressive Agents, administration & dosage, Male, Microscopic Polyangiitis, drug therapy, Middle Aged, Remission Induction, Retrospective Studies, Treatment Failure, Treatment Outcome, Young Adult